| 2.46 0.06 (2.5%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.05 | 1-year : | 3.5 |
| Resists | First : | 2.61 | Second : | 3 |
| Pivot price | 2.37 |
|||
| Supports | First : | 2 | Second : | 1.66 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.44  |
| MA(100) : | 3.42 |
MA(250) : | 4.37 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 51.5 |
D(3) : | 42.5 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 7.48 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRPH ] has closed below upper band by 32.5%. Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.48 - 2.49 | 2.49 - 2.5 |
| Low: | 2.32 - 2.34 | 2.34 - 2.35 |
| Close: | 2.44 - 2.46 | 2.46 - 2.48 |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Thu, 26 Sep 2024
ProPhase Labs stock hits 52-week low at $2.02 By Investing.com - Investing.com Australia
Mon, 19 Aug 2024
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event - Yahoo Finance
Wed, 07 Aug 2024
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14 - Yahoo Finance
Thu, 11 Jul 2024
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress - GlobeNewswire
Wed, 15 May 2024
ProPhase Labs: Hidden Gem With An AI Kicker (NASDAQ:PRPH) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 19 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 256 (K) |
| Shares Short P.Month | 276 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.3 |
| Profit Margin | -146.4 % |
| Operating Margin | -316.4 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -51 % |
| Qtrly Rev. Growth | -81.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.94 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.67 |
| PEG Ratio | 0 |
| Price to Book value | 1.06 |
| Price to Sales | 2.61 |
| Price to Cash Flow | -3.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|